Recombinant 9 Valent Human Papillomavirus Vaccine(Pichia)(Yidao Biotechnology)

Phase I study: The main purpose is to evaluate the safety of different doses of adjuvanted test vaccine inoculated in the population aged 18-45 years. The secondary purpose is to preliminarily explore the immunogenicity of different doses of adjuvanted test vaccine inoculated in the population aged 18-45 years. The purpose of Phase II study: To evaluate the immunogenicity and safety of different doses of adjuvanted test vaccine inoculated in female population aged 18-45 years according to two immunization schedules of 0, 2 months or 0, 6 months, and to explore the optimal ratio of adjuvant dose and immunization schedule.